Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Stockholders' Deficit

v2.4.0.8
Condensed Consolidated Statements of Stockholders' Deficit (USD $)
Total
Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Series B [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2012 $ (26,144,245) $ 16,675,983   $ 9,920 $ 1,047,936 $ (26,144,245)
Beginning balance, shares at Dec. 31, 2012   15,799,291   15,065,931    
Issuance of stock in exchange for cash     4,294,259      
Issuance of stock in exchange for cash, shares     4,083,225      
Issuance of stock upon conversion of convertible debt and accrued interest     6,490,071      
Issuance of stock upon conversion of convertible debt and accrued interest, shares     6,041,356      
Issuance of common stock warrants 136,380    275    136,380   
Issuance of common stock upon exercise of options 65,593    (136,380) 94 65,499   
Issuance of common stock upon exercise of options, shares        771,341    
Common stock repurchased (189)      (2) 187   
Common stock repurchased, shares        (2,857)    
Vesting of early exercised options 3,974      13 3,961   
Compensation expense for options issued a non-employee 4,679         4,679   
Stock-based compensation expense 390,618         390,618   
Effect of merger and recapitalization of share amounts         5,809 (5,809)   
Issuance of shares to stockholders of Ekso Bionics Holdings         5,280 (5,280)   
Issuance of shares to stockholders of Ekso Bionics Holdings, shares 5,280,368      5,280,368    
Net loss (11,887,374)            (11,887,374)
Ending balance at Dec. 31, 2013 (36,372,708) 27,324,208   21,114 1,637,797 (38,031,619)
Ending balance, shares at Dec. 31, 2013   25,923,872   21,114,783    
Issuance of common stock upon exercise of options 1,910      90 1,820   
Issuance of common stock upon exercise of options, shares        90,057    
Fair value of warrant liability/obligation transferred to equity 281,987         281,987   
Fair value of warrant liability transferred to equity, shares   767,212         
Conversion of preferred stock 27,324,208 (27,324,208)   26,691 27,297,517   
Conversion of preferred stock, shares converted   26,691,084         
Conversion of preferred stock, shares issued        26,691,084    
Ending balance at Jan. 14, 2014 (8,764,603)      47,895 29,219,121 (38,031,619)
Ending balance, shares at Jan. 14, 2014        47,895,924    
Issuance of stock in exchange for cash 25,300,000      25,300 25,274,700   
Issuance of stock in exchange for cash, shares        25,300,000    
Issuance of stock upon conversion of convertible debt and accrued interest 5,082,578      5,000 5,077,578   
Issuance of stock upon conversion of convertible debt and accrued interest, shares        5,000,000    
Shares issued to consultant         250 (250)   
Shares issued to consultant, shares        250,000    
Offering costs (4,250,744)         (4,250,744)   
Issuance of common stock warrants (10,613,550)         (10,613,550)   
Fair value of warrant liability/obligation transferred to equity 95,760         95,760   
Ending balance at Jan. 16, 2014 6,849,441      78,445 44,802,615 (38,031,619)
Ending balance, shares at Jan. 16, 2014        78,445,924    
Offering costs (34,962)         (34,962)   
Issuance of common stock upon exercise of options 67,196      139 67,057   
Issuance of common stock upon exercise of options, shares        138,249    
Stock-based compensation expense 810,399         810,399   
Net loss (13,614,016)            (13,614,016)
Ending balance at Sep. 30, 2014 $ (5,921,942)      $ 78,584 $ 45,645,109 $ (51,645,635)
Ending balance, shares at Sep. 30, 2014        78,584,173